If you have been reading about glucagon receptor and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-03-04. Where a claim depends on a specific study, the study is described rather than over-claimed.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
Identification and purity assessment rely on established analytical techniques. Reverse-phase high-performance liquid chromatography separates the compound from related impurities and degradation products. Mass spectrometry confirms molecular identity and detects modifications that change the expected mass. Additional methods such as amino acid analysis or capillary electrophoresis may be used for verification. Small differences in sample preparation can influence results, so procedures are usually controlled and documented in detail. Consistency between runs supports confidence in reported values.
Stability studies examine how the molecule changes under defined conditions of temperature, humidity, and light exposure over time. Results are used to set storage recommendations and shelf-life limits. In practice, lyophilized peptide material is often stored at low temperatures to slow degradation, while reconstituted solutions are handled more carefully because they are generally less stable. Reported stability data apply to specific formulations and conditions, so extrapolation to other preparations requires caution.
Retatrutide is handled in laboratories mainly as a lyophilized solid for analytical and biochemical research. The peptide is typically supplied as a white to off-white powder and is reconstituted in appropriate solvents before use. Because peptide-based molecules are sensitive to temperature, moisture, and repeated freeze-thaw cycles, proper storage conditions affect both stability and measurement accuracy. Laboratories generally follow documented handling procedures to maintain the integrity of the material across experiments.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic triple-agonist peptide | Single linear chain carrying three receptor activities |
| Reported molecular weight | Approximately 4731 Da | Calculated from the published sequence; sources vary slightly |
| Appearance | White to off-white lyophilized powder | Typical of purified research-grade peptides |
| Solubility | Freely soluble in water; poorly soluble in nonpolar solvents | Dissolves in aqueous buffer near neutral pH |
| Storage of dry powder | -20 °C or below, desiccated, protected from light | Avoid repeated temperature cycling |
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Quality control of research material relies on several complementary checks. Purity testing confirms the absence of truncated or oxidized peptide species, while water content and counterion analysis show how much mass comes from salts rather than the peptide itself. Sequence verification through tandem mass spectrometry ensures the correct amino acid chain. Because unregulated suppliers vary widely, independent verification of identity and purity is often necessary before a sample enters experiments.
Documentation plays a practical role in maintaining consistent results across laboratories. Certificates of analysis list purity, identity, and testing methods, and batch numbers allow comparisons between lots. Records of storage temperature and handling history help investigators interpret unexpected findings. When a sample behaves anomalously, reviewing that documentation often reveals whether the cause lies in the material or in the assay conditions.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
The Cubans and Soviets concurred with FAPLA's decision to withdraw to Cuito Cuanavale, with Castro pointing out that a strong defensive stand could plausibly be made there if the brigades managed to reach it. He also suggested that the only way to defeat the South African expeditionary forces in the long term was to outflank them and apply pressure to the South West African border. This would entail opening up yet another military front, in southwestern Angola, well south of Cuito Cuanavale. On 15 November, dos Santos had written a letter to Castro requesting direct Cuban military assistance against the SADF. Castro agreed on the condition that he and General Arnaldo Ochoa receive command of all FAPLA forces on the front. The Soviet military mission was notably excluded from all future operational planning. Shortly afterwards, the Cuban government authorised the deployment of an armoured brigade and several air defence units—about 3,000 personnel—to Cuito Cuanavale. Castro suspected that the South Africans would not be content with eliminating FAPLA east of the town and that they intended to take control of Cuito Cuanavale's strategic airfield as well. His strategy was to strengthen the defence of that settlement while making preparations to vastly increase the Cuban troop presence at Lobito, near the South West African border. The FAPLA and Cuban defenders now ringed their defensive positions with minefields and interlocking fields of fire from dug-in tanks and field guns, into which they channelled SADF assaults.
==== Bacteria adhesion mediated by shear stress ==== Similar to selectin binding, FimH binding also have a threshold where it only starts binding to the host cells above this threshold. This shear stress threshold is about 1 dynes per squared centimeter, slightly larger than that of selectin binding. Above this threshold, FimH also alternate between binding, pause and unbinding with the mannose residues. However, different from selectin binding, FimH binding to mannose-BSA can either have a very long or very short pauses. This cause FimH binding to exhibit a "stick-and-roll" adhesion, not rolling adhesion in the case of selectin binding. And unlike selectin binding which requires integrin to help with firm adhesion, FimH binding can become stationary, and this process is reversible. All of this is mediated by shear stress level: at shear stress higher than 20 dynes per squared centimeter, FimH binding is stationary. At shear stress higher than 100 dynes per squared centimeter, slow rolling is observed.
Another use for nuclear magnetic resonance is data acquisition in the petroleum industry for petroleum and natural gas exploration and recovery. Initial research in this domain began in the 1950s, however, the first commercial instruments were not released until the early 1990s. A borehole is drilled into rock and sedimentary strata into which nuclear magnetic resonance logging equipment is lowered. Nuclear magnetic resonance analysis of these boreholes is used to measure rock porosity, estimate permeability from pore size distribution and identify pore fluids (water, oil and gas). These instruments are typically low field NMR spectrometers. NMR logging, a subcategory of electromagnetic logging, measures the induced magnet moment of hydrogen nuclei (protons) contained within the fluid-filled pore space of porous media (reservoir rocks). Unlike conventional logging measurements (e.g., acoustic, density, neutron, and resistivity), which respond to both the rock matrix and fluid properties and are strongly dependent on mineralogy, NMR-logging measurements respond to the presence of hydrogen. Because hydrogen atoms primarily occur in pore fluids, NMR effectively responds to the volume, composition, viscosity, and distribution of these fluids, for example oil, gas or water. NMR logs provide information about the quantities of fluids present, the properties of these fluids, and the sizes of the pores containing these fluids. From this information, it is possible to infer or estimate:
recent surgery (both for thromboembolism and air embolism) previous stroke or cardiovascular disease a history of long-term intravenous therapy (for air embolism) Bone fracture (for fat embolism) A septal defect of the heart makes it possible for paradoxical embolization, which happens when a clot in a vein enters the right side of the heart and passes through a hole into the left side. The clot can then move to an artery and cause arterial embolisation.
Sources: en.wikipedia.org
==== 1.C Pore-forming toxins (proteins and peptides) ==== 1.C.3 α-Hemolysin (αHL) family 1.C.4 Aerolysin family 1.C.5 ε-toxin family 1.C.11 RTX-toxin superfamily 1.C.12 Membrane attack complex/perforin superfamily 1.C.13 Leukocidin family 1.C.14 Cytohemolysin (CHL) family 1.C.39 Thiol-activated cholesterol-dependent cytolysin family 1.C.43 Lysenin family 1.C.56 Pseudomonas syringae HrpZ cation channel family 1.C.57 Clostridial cytotoxin family 1.C.58 The Microcin E492/C24 (Microcin E492) Family 1.C.74 Snake cytotoxin (SCT) family 1.C.97 Pleurotolysin pore-forming family
In 1875, Franz Joseph became the principal heir to the substantial fortune left by his predecessor and uncle, Ferdinand I, which consisted mainly of the Bohemian estates of the Duke of Reichstadt. In 1885, Franz Joseph met Katharina Schratt, a leading actress of the Vienna stage, and she became his friend and confidante. This relationship lasted the rest of his life, and was—to a certain degree—tolerated by Elisabeth. Franz Joseph built Villa Schratt in Bad Ischl for her, and also provided her with a small palace in Vienna. Though their relationship lasted for 34 years, it remained platonic. The empress was an inveterate traveller, horsewoman, and fashion maven who was rarely seen in Vienna. Sisi was obsessed about preserving her beauty, carrying out many bizarre routines and strenuous exercise, and as a result suffered from ill health. She was stabbed to death by an Italian anarchist in 1898 while on a visit to Geneva. A few days after the funeral, Robert of Parma wrote in a letter to his friend Tirso de Olazábal that "It was pitiful to look at the Emperor, he showed a great deal of energy in his immense pain, but at times one could see all the immensity of his grief." Franz Joseph never fully recovered from the loss. According to the future empress Zita of Bourbon-Parma he told his relatives: "You'll never know how important she was to me" or, according to some sources, "You will never know how much I loved this woman."
The spread of ironworking in Central and Western Europe is associated with Celtic expansion. According to Pliny the Elder, iron use was common in the Roman era. In the lands of what is now considered China, iron appears approximately 700–500 BC. Iron smelting may have been introduced into China through Central Asia. The earliest evidence of the use of a blast furnace in China dates to the 1st century AD, and cupola furnaces were used as early as the Warring States period (403–221 BC). Usage of the blast and cupola furnace remained widespread during the Tang and Song dynasties. During the Industrial Revolution in Britain, Henry Cort began refining iron from pig iron to wrought iron (or bar iron) using innovative production systems. In 1783 he patented the puddling process for refining iron ore. It was later improved by others, including Joseph Hall.
== Combined endpoint == Some studies will examine the incidence of a combined endpoint, which can merge a variety of outcomes into one group. For example, the heart attack study above may report the incidence of the combined endpoint of chest pain, myocardial infarction, or death. An example of a cancer study powered for a combined endpoint is disease-free survival; trial participants experiencing either death or discovery of any recurrence would constitute the endpoint. Overall Treatment Utility is an example of a multidimensional composite endpoint in cancer clinical trials. Regarding humane endpoints, a combined endpoint may constitute a threshold where there is enough cumulative degree of disease, symptoms, signs or laboratory abnormalities to motivate an intervention.
== Gliding scandals == During the 2020 Women's World Gliding Championships at Lake Keepit, Australia, the home team captain Terry Cubley (Executive Officer of the GFA) was charged with unsporting behaviour for hacking the official tracking system to bypass the mandatory 15 minute delay and forward real time competitors' positions to his team, granting a tactical advantage. An investigation revealed that Matt Gage had been closely involved with the developers of the tracking system, and was aware of an undocumented back door that allowed the team captain (Terry Cubley) to bypass the 15 minute delay. This real-time information was relayed by the team captain over the radio to the Australian pilots. This was the first time in the sport's history that an entire team had been penalised for unsporting behaviour, with the Competition Director applying a penalty of 25 points per pilot per day. Controversially the pilots involved were spared disqualification only receiving a relatively trivial points reduction (compared to a competing pilot who was disqualified for infringing airspace earlier in the competition). Following a subsequent GFA investigation two of the Australian Team admitted to cheating and the GFA made a formal apology to the FAI and the wider gliding community. Terry Cubley was removed from his role as Vice President of the IGC, but chose to remain as Executive Officer of the GFA . The pilots involved chose to appeal against this decision, resulting in the longest and most comprehensive investigation in the FAIs history.
Sources: en.wikipedia.org
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.
No. As of the most recent public information it remains investigational in every jurisdiction. Material sold under this name outside trials is a research chemical, not an approved medicine. Current status should always be checked against regulator notices.
Dual agonists act on two receptors, usually GIP and GLP-1. Retatrutide adds glucagon receptor activity, which is associated with increased energy expenditure. Whether that third component adds clinically meaningful benefit over dual agonism remains an open question.
Reverse-phase liquid chromatography and mass spectrometry are the most common techniques. Chromatography assesses purity, while mass spectrometry confirms molecular identity. Additional methods may be applied when higher confidence is required.